- Newsletter
- May 2024
Global
From €1010EUR$1,134USD£890GBP
- Report
- March 2024
- 175 Pages
Global
From €4770EUR$5,000USD£4,061GBP
- Report
- February 2024
- 175 Pages
Global
From €4770EUR$5,000USD£4,061GBP
- Report
- February 2024
- 175 Pages
Global
From €4770EUR$5,000USD£4,061GBP
- Report
- May 2020
- 185 Pages
Global
From €3959EUR$4,150USD£3,371GBP
- Report
- July 2022
- 100 Pages
Global
From €2623EUR$2,750USD£2,234GBP
- Drug Pipelines
- April 2021
- 64 Pages
Global
€20988EUR$22,000USD£17,870GBP
- Report
- July 2018
- 33 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 16 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 17 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 17 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 30 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 21 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Drug Pipelines
- February 2018
- 16 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- March 2020
- 154 Pages
Global
From €10489EUR$10,995USD£8,931GBP
- Report
- March 2018
- 113 Pages
Global
From €2623EUR$2,750USD£2,234GBP
- Report
- July 2018
- 20 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 11 Pages
Global
From €9540EUR$10,000USD£8,123GBP
- Report
- July 2018
- 20 Pages
Global
From €9540EUR$10,000USD£8,123GBP
The Long Acting Muscarinic Antagonist (LAMA) market is a subset of the larger respiratory drug market. LAMAs are used to treat chronic obstructive pulmonary disease (COPD) and asthma. These drugs work by blocking the action of acetylcholine, a neurotransmitter that causes airway constriction. This helps to reduce symptoms such as coughing, wheezing, and shortness of breath. LAMAs are typically administered via inhalation, and are available in both short-acting and long-acting formulations. Long-acting formulations provide sustained relief from symptoms over a longer period of time.
Some of the major companies in the LAMA market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. These companies produce a variety of LAMA drugs, including tiotropium, aclidinium, umeclidinium, and glycopyrronium. Show Less Read more